An Australian stem cell and regenerative medicine company

April 07, 2020

Growing interest in stem cells for COVID-19 ailments

Read an article published in BioProcess International which explores Cynata’s interest in this area.

Read Story

April 03, 2020

Cynata Therapeutics (ASX:CYP) 1H20 results & outlook

Finance News Network discusses with Cynata CEO Dr Ross Macdonald the Company’s 1H20 results, upcoming Phase 2 clinical trials, licensing and strategy to build the company's Cymerus cell therapy platform

Read More

January 31, 2020

Feature article in “Clinical Leader” on Cynata’s osteoarthritis program: “Stem Cell Therapy Trial Offers Hope To Osteoarthritis Patients”

Ed Miseta, Clinical Leader’s Chief Editor, discusses Cynata’s osteoarthritis clinical program and general therapeutic stem cell topics with Cynata’s CEO, Dr Ross Macdonald and COO, Dr Kilian Kelly.

Read entire story

November 13, 2019

Manufacturing MSCs for commercial application: an interview with Ross Macdonald

In this interview Ross Macdonald discusses Cynata’s unique approach to the manufacture of therapeutic mesenchymal stem/stromal cells from induced pluripotent stem cells and why this provides the Company with an important competitive advantage.

October 11, 2019

Cynata Therapeutics’ parallel approaches to market

Source: Licensing Executives Society (LEX) Newsstand - Powered by Lexology

In 2014, Cynata Therapeutics commenced technology transfer and product development, and simultaneously commenced consultation with regulatory authorities regarding the approval pathways for its cellular therapy products.